IP Library Granted Patent US 8,309,566
Granted Patent B2
US 8,309,566 · App. 12/371,550 · Granted Nov 13, 2012

Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,309,566
App. No.
12/371,550
Granted
Nov 13, 2012
Kind
B2
Abstract

This invention is directed to compounds of formula (I): where n, m, Y, R 1 , R 2 , R 3 , R 4 and R 5 are disclosed herein, as isolated stereoisomers or mixtures thereof, or as pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising the compounds of formula (I); and methods of using the compounds and the pharmaceutical compositions in treating diseases or conditions associated with JAK2 activity.

Claims (80)

1. A compound of formula (Ia):

or a pharmaceutically acceptable salt thereof, wherein:

n is 0, 1 or 2;

m is 0, 1 or 2;

Y is selected from the group consisting of ═C(R 6 )— and ═N—;

R 1 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkenyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, —R 8 —C(O)OR 6 , —R 9 —N(R 6 )R 7 and —R 9 —OR 6 ;

each R 2 , when present, is independently selected from the group consisting of optionally substituted alkyl, halo, cyano and —OR 6 ;

each R 3 , when present, is independently selected from the group consisting of alkyl, halo and haloalkyl;

R 4 is selected from the group consisting of aryl and heteroaryl, where the aryl and the heteroaryl are each independently optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl, cyano, N-heterocyclyl, N-heteroaryl, aryl, —R 8 —OR 6a , —R 8 —S(O) p R 6a (where p is 0, 1 or 2), —R 8 —C(O)R 6a , —R 8 —C(O)OR 6a , —R 8 —C(O)N(R 6a )R 7a , —R 8 —N(R 6a )R 7a , —R 8 —N(R 6a )—R 9 —N(R 6a )R 7a , —R 8 —N(R 6a )—R 9 —OR 7a , —R 8 —N(R 6a )C(O)R 7a , —R 8 —N(R 6a )S(O) 2 R 7a , —R 8 —N(R 6a )C(O)—R 8 —N(R 6a )R 7a , and —R 8 —N(R 6a )—R 9 —N(R 6a )S(O) 2 R 7a , where each R 6a and R 7a is independently selected from the group consisting of hydrogen, alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted aralkyl, and where the N-heterocyclyl, the N-heteroaryl and the aryl are each independently optionally substituted by one or more substituents selected from the group consisting of —C(O)R 6 , —R 8 —N(R 6 )R 7 , —R 8 —C(O)N(R 6 )R 7 , alkyl, halo and optionally substituted aryl;

R 5 is an N-heterocyclyl, wherein a nitrogen atom in the N-heterocyclyl is optionally substituted by a substituent selected from the group consisting of alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted heteroarylalkynyl, —R 8 —OR 6 , —R 8 —C(O)R 6 , —R 8 —C(O)OR 6 , —R 9 —N(R 6 )R 7 , —R 8 —C(O)N(R 6 )R 7 , —R 8 —C(N═R 6 )N(R 6 )R 7 , —R 8 —S(O) 2 N(R 6 )R 7 , and —R 8 —S(O) t R 6 (where t is 1 or 2); and a carbon atom in the N-heterocyclyl is optionally substituted by a substituent selected from the group consisting of alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkynyl, oxo, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted heteroarylalkynyl, —R 8 —OR 6 , —R 8 —C(O)R 6 , —R 8 —C(O)OR 6 , —R 9 —N(R 6 )R 7 , —R 8 —C(O)N(R 6 )R 7 , —R 8 —S(O) 2 N(R 6 )R 7 , and —R 8 —S(O) p R 6 (where p is 0, 1 or 2);

each R 6 and each R 7 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, and optionally substituted heteroarylalkynyl; or any R 6 and R 7 , together with the common nitrogen to which they are both attached, form an optionally substituted N-heteroaryl or an optionally substituted N-heterocyclyl;

each R 8 is independently selected from the group consisting of a direct bond, an optionally substituted straight or branched alkylene chain, an optionally substituted straight or branched alkenylene chain and an optionally substituted straight or branched alkynylene chain; and

each R 9 is independently selected from the group consisting of an optionally substituted straight or branched alkylene chain, an optionally substituted straight or branched alkenylene chain and an optionally substituted straight or branched alkynylene chain;

provided at least one of R 5 and a substituent on R 4 is a bridged N-heterocyclyl;

as an isolated stereoisomer or a mixture thereof.

2. A compound of claim 1 wherein m is 0 or 1; R 2 , when present, is in a meta position relative to the nitrogen bearing R 1 ; and R 5 is in the para position relative to the nitrogen bearing R 1 .

3. A compound of claim 1 wherein n is 0 or 1; and R 3 , when present, is at the 5-position of the pyrimidinyl ring.

4. A compound of claim 1 wherein m is 0 or 1; n is 0 or 1; R 2 , when present, is in a meta position relative to the nitrogen bearing R 1 ; R 3 , when present, is at the 5-position of the pyrimidinyl ring; and R 5 is in the para position relative to the nitrogen bearing R 1 .

5. The compound of claim 1 according to formula (Ia-1):

6. The compound of claim 5 selected from the group consisting of

wherein:

each R 2a is independently selected from hydrogen, alkyl, halo, cyano and —OR 6 ;

each R 5a is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted heteroarylalkynyl, —R 8 —OR 6 , —R 8 —C(O)R 6 , —R 8 —C(O)OR 6 , —R 9 —N(R 6 )R 7 , —R 8 —C(O)N(R 6 )R 7 , —R 8 —C(N═R 6 )N(R 6 )R 7 , —R 8 —S(O) 2 N(R 6 )R 7 , and —R 8 —S(O) t R 6 (where t is 1 or 2).

7. The compound of claim 6 wherein:

each n is 0 or 1;

each R 4 is independently selected from the group consisting of phenyl, benzimidazolyl, benzo[b][1,4]oxazinyl, benzo[b]azepinyl, 2,3,4,5-tetrahydro-1H-benzo[b]azepinyl, 3,4-dihydro-2H-benzo[b][1,4]thiazinyl, 3′,4′-dihydrospiro[cyclobutane-1,2′-pyrido[3,2-b][1,4]oxazinyl, 3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazinyl, 3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazinyl, imidazo[1,2-a]pyridinyl, 6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indolyl, 7,8,9,9a-tetrahydro-5H-pyrido[2,3-e]pyrrolo[1,2-a][1,4]diazepin-10(11H)-onyl, indolyl, indolinyl, naphthyridinyl, pyrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyrrolyl, 1H-pyrrolo[2,3-b]pyridinyl, and thiazolyl, each optionally substituted by one or more substituents independently selected from the group consisting of oxo, alkyl, halo, haloalkyl, cyano, N-heterocyclyl, N-heteroaryl, aryl, —R 8 —OR 6a , —R 8 —S(O) p R 6a (where p is 0, 1 or 2), —R 8 —C(O)R 6a , —R 8 —C(O)OR 6a , —R 8 —C(O)N(R 6a )R 7a , —R 8 —N(R 6a )R 7a , —R 8 —N(R 6a )—R 9 —N(R 6a )R 7a , —R 8 —N(R 6a )—R 9 —OR 7a , —R 8 —N(R 6a )C(O)R 7a , —R 8 —NR 6a )S(O) 2 R 7a , —R 8 —N(R 6a )C(O)—R 8 —N(R 6a )R 7a , and —R 8 —N(R 6a )—R 9 —N(R 6a )S(O) 2 R 7a , where the N-heterocyclyl, the N-heteroaryl and the aryl are each independently optionally substituted by one or more substituents selected from the group consisting of —C(O)R 6 , —R 8 —N(R 6 )R 7 , —R 8 —C(O)N(R 6 )R 7 , alkyl, halo and optionally substituted aryl;

each R 6a and R 7a is independently selected from the group consisting of hydrogen, alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted aralkyl;

each R 8 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; and

each R 9 is an optionally substituted straight or branched alkylene chain.

8. The compound of claim 7 according to formula (Ia-1a):

9. The compound of claim 7 according to formula (Ia-1b):

10. The compound of claim 7 according to formula (Ia-1c):

11. The compound of claim 7 according to formula (Ia-1d):

12. The compound of claim 7 according to formula (Ia-1e):

13. The compound of claim 7 according to formula (Ia-1f):

14. The compound of claim 7 according to formula (Ia-1g):

15. The compound of claim 7 according to formula (Ia-1h):

16. The compound of claim 7 according to formula (Ia-1i):

17. The compound of claim 7 according to formula (Ia-1j):

18. The compound of claim 7 according to formula (Ia-1k):

19. The compound of claim 7 according to formula (Ia-1l):

20. The compound of claim 5 wherein:

n is 0 or 1;

m is 0 or 1;

R 1 is selected from the group consisting of hydrogen or alkyl;

R 2 is independently selected from the group consisting of optionally substituted alkyl, halo, cyano and —OR 6 ;

R 3 is independently selected from the group consisting of alkyl, halo and haloalkyl;

R 4 is heteroaryl optionally substituted by a bridged N-heterocyclyl, where the bridged N-heterocyclyl is optionally substituted by one or more substituents selected from the group consisting of alkyl, halo and optionally substituted aryl;

R 5 is a non-bridged N-heterocyclyl, wherein a nitrogen atom in the non-bridged N-heterocyclyl is optionally substituted by a substituent selected from the group consisting of alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, —R 8 —C(O)R 6 , —R 8 —C(O)OR 6 , —R 9 —N(R 6 )R 7 , —R 8 —C(O)N(R 6 )R 7 , —R 8 —S(O) 2 N(R 6 )R 7 , and —R 8 —S(O) t R 6 (where t is 1 or 2); and wherein a carbon atom in the non-bridged N-heterocyclyl is optionally substituted by a substituent selected from the group consisting of alkyl, halo, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, —R 8 —OR 6 , C(O)OR 6 , —R 9 —N(R 6 )R 7 , —R 8 —C(O)N(R 6 )R 7 , —R 8 —S(O) 2 N(R 6 )R 7 , and —R 8 —S(O) p R 6 (where p is 0, 1 or 2);

each R 6 and each R 7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl; or any R 6 and R 7 , together with the common nitrogen to which they are both attached, form an optionally substituted N-heteroaryl or an optionally substituted N-heterocyclyl;

each R 8 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; and

each R 9 is an optionally substituted straight or branched alkylene chain.

21. The compound of claim 1 according to formula (Ia-2):

22. The compound of claim 21 selected from the group consisting of:

wherein:

each R 5a is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, halo alkyl, haloalkenyl, haloalkynyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted heteroarylalkynyl, —R 8 —OR 6 , —R 8 —C(O)R 6 , —R 8 —C(O)OR 6 , —R 9 —N(R 6 )R 7 , —R 8 —C(O)N(R 6 )R 7 , —R 8 —C(N═R 6 )N(R 6 )R 7 , —R 8 —S(O) 2 N(R 6 )R 7 , and —R 8 —S(O) t R 6 (where t is 1 or 2).

23. The compound of claim 22 wherein:

each n is 0 or 1;

each m is 0 or 1;

each R 4 is independently selected from the group consisting of phenyl, benzimidazolyl, benzo[b][1,4]oxazinyl, benzo[b]azepinyl, 2,3,4,5-tetrahydro-1H-benzo[b]azepinyl, 3,4-dihydro-2H-benzo[b][1,4]thiazinyl, 3′,4′-dihydrospiro[cyclobutane-1,2′-pyrido[3,2-b][1,4]oxazinyl, 3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazinyl, 3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazinyl, imidazo[1,2-a]pyridinyl, 6,7,8,9-tetrahydro-5H-pyrido[2,3-b]indolyl, 7,8,9,9a-tetrahydro-5H-pyrido[2,3-e]pyrrolo[1,2-a][1,4]diazepin-10(11H)-onyl, indolyl, indolinyl, naphthyridinyl, pyrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyrrolyl, 1H-pyrrolo[2,3-b]pyridinyl, and thiazolyl, each optionally substituted by one or more substituents independently selected from the group consisting of oxo, alkyl, halo, haloalkyl, cyano, N-heterocyclyl, N-heteroaryl, aryl, —R 8 —OR 6a , —R 8 —S(O) p R 6a (where p is 0, 1 or 2), —R 8 —C(O)R 6a , —R 8 —C(O)OR 6a , —R 8 —C(O)N(R 6a )R 7a , —R 8 —N(R 6a )R 7a , —R 8 —N(R 6a )—R 9 —N(R 6a )R 7a , —R 8 —N(R 6a )—R 9 —OR 7a , —R 8 —N(R 6a )C(O)R 7a , —R 8 —N(R 6a )S(O) 2 R 7a , —R 8 —N(R 6a )C(O)—R 8 —N(R 6a )R 7a , and —R 8 —N(R 6a )—R 9 —N(R 6a )S(O) 2 R 7a , where the N-heterocyclyl, the N-heteroaryl and the aryl are each independently optionally substituted by one or more substituents selected from the group consisting of —C(O)R 6 , —R 8 —N(R 6 )R 7 , —R 8 —C(O)N(R 6 )R 7 , alkyl, halo and optionally substituted aryl;

each R 6a and R 7a is independently selected from the group consisting of hydrogen, alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted aralkyl;

each R 8 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; and

each R 9 is an optionally substituted straight or branched alkylene chain.

24. The compound of claim 23 according to formula (Ia-2a):

25. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of a compound of formula (Ia):

or as a pharmaceutically acceptable salt thereof, wherein:

n is 0, 1 or 2;

m is 0, 1 or 2;

Y is selected from the group consisting of ═C(R 6 )— and ═N—;

R 1 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkenyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, —R 8 —C(O)OR 6 , —R 9 —N(R 6 )R 7 and —R 9 —OR 6 ;

each R 2 , when present, is independently selected from the group consisting of optionally substituted alkyl, halo, cyano and —OR 6 ;

each R 3 , when present, is independently selected from the group consisting of alkyl, halo and haloalkyl;

R 4 is selected from the group consisting of aryl and heteroaryl, where the aryl and the heteroaryl are each independently optionally substituted by one or more substituents selected from the group consisting of oxo, alkyl, halo, haloalkyl, cyano, N-heterocyclyl, N-heteroaryl, aryl, —R 8 —OR 6a , —R 8 —S(O) p R 6a (where p is 0, 1 or 2), —R 8 —C(O)R 6a , —R 8 —C(O)OR 6a , —R 8 —C(O)N(R 6a )R 7a , —R 8 —N(R 6a )R 7a , —R 8 —N(R 6a )—R 9 —N(R 6a )R 7a , —R 8 —N(R 6a )—R 9 —OR 7a , —R 8 —N(R 6a )C(O)R 7a , —R 8 —N(R 6a )S(O) 2 R 7a , —R 8 —N(R 6a )C(O)—R 8 —N(R 6a )R 7a , and —R 8 —N(R 6a )—R 9 —N(R 6a )S(O) 2 R 7a , where each R 6a and R 7a is independently selected from the group consisting of hydrogen, alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted aralkyl, and where the N-heterocyclyl, the N-heteroaryl and the aryl are each independently optionally substituted by one or more substituents selected from the group consisting of —C(O)R 6 , —R 8 —N(R 6 )R 7 , —R 8 —C(O)N(R 6 )R 7 , alkyl, halo and optionally substituted aryl;

R 5 is an N-heterocyclyl, wherein a nitrogen atom in the N-heterocyclyl is optionally substituted by a substituent selected from the group consisting of alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted heteroarylalkynyl, —R 8 —OR 6 , —R 8 —C(O)R 6 , —R 8 —C(O)OR 6 , —R 9 —N(R 6 )R 7 , —R 8 —C(O)N(R 6 )R 7 , —R 8 —C(N═R 6 )N(R 6 )R 7 , —R 8 —S(O) 2 N(R 6 )R 7 , and —R 8 —S(O) t R 6 (where t is 1 or 2); and a carbon atom in the N-heterocyclyl is optionally substituted by a substituent selected from the group consisting of alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkynyl, oxo, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted heteroarylalkynyl, —R 8 —OR 6 , —R 8 —C(O)R 6 , —R 8 —C(O)OR 6 , —R 9 —N(R 6 )R 7 , —R 8 —C(O)N(R 6 )R 7 , —R 8 —S(O) 2 N(R 6 )R 7 , and —R 8 —S(O) p R 6 (where p is 0, 1 or 2);

each R 6 and each R 7 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, and optionally substituted heteroarylalkynyl; or any R 6 and R 7 , together with the common nitrogen to which they are both attached, form an optionally substituted N-heteroaryl or an optionally substituted N-heterocyclyl;

each R 8 is independently selected from the group consisting of a direct bond, an optionally substituted straight or branched alkylene chain, an optionally substituted straight or branched alkenylene chain and an optionally substituted straight or branched alkynylene chain; and

each R 9 is independently selected from the group consisting of an optionally substituted straight or branched alkylene chain, an optionally substituted straight or branched alkenylene chain and an optionally substituted straight or branched alkynylene chain;

provided at least one of R 5 and a substituent on R 4 is a bridged N-heterocyclyl;

as an isolated stereoisomer or a mixture thereof.

26. A compound which is 4-(6-(morpholin-4-yl)pyridin-3-yl)-N-(3-methyl-4-((1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)phenyl)pyrimidin-2-amine, or a pharmaceutically acceptable salt thereof.

Assignments (3)
SECURITY INTEREST Recorded Aug 25, 2022
From: RIGEL PHARMACEUTICALS, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 061327/0712 →
CORRECTIVE ASSIGNMENT TO CORRECT THE SPELLING OF THE 5TH NAMED INVENTOR PREVIOUSLY RECORDED AT REEL: 023063 FRAME: 0866. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Aug 25, 2014
From: BHAMIDIPATI, SOMASEKHAR; CLOUGH, JEFFREY; ARGADE, ANKUSH; SINGH, RAJINDER; MARKOVTSOV, VADIM; DING, PINGYU; YU, JIAXIN; ATUEGBU, ANDY; HONG, HUI; DARWISH, IHAB; THOTA, SAMBAIAH
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 033608/0837 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 6, 2009
From: BHAMIDIPATI, SOMASEKHAR; CLOUGH, JEFFREY; ARGADE, ANKUSH; SINGH, RAJINDER; MARKOVTOSOV, VADIM; DING, PINGYU; YU, JIAXIN; ATUEGBU, ANDY; HONG, HUI; DARWISH, IHAB; THOTA, SAMBAIAH
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 023063/0866 →